Compare · AYLA vs KVUE
AYLA vs KVUE
Side-by-side comparison of Ayala Pharmaceuticals Inc. (AYLA) and Kenvue Inc. (KVUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYLA and KVUE operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- KVUE is the larger of the two at $35.86B, about 477.4x AYLA ($75.1M).
- KVUE has hit the wire 15 times in the past 4 weeks while AYLA has been quiet.
- KVUE has more recent analyst coverage (25 ratings vs 5 for AYLA).
- Company
- Ayala Pharmaceuticals Inc.
- Kenvue Inc.
- Price
- -
- -
- Market cap
- $75.1M
- $35.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2023
- News (4w)
- 0
- 15
- Recent ratings
- 5
- 25
Ayala Pharmaceuticals Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Latest AYLA
- SEC Form 3 filed by new insider Martell Bridget A
- SEC Form 3 filed by new insider Orbach Pini
- SEC Form 3 filed by new insider Golan Roy
- SEC Form 10-K filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.
- Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets
- SEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company
Latest KVUE
- SEC Form 8-K filed by Kenvue Inc.
- Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- SEC Form 4 filed by Kenvue Inc.
- Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
- LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion